GPB SCIENTIFIC

An experienced management, scientific and technical team with deep domain expertise

GPB Scientific has assembled a seasoned core team and strong advisors to drive the development and commercialization of our turnkey point-of-collection cell purification/enrichment system for CAR-T and other cell therapies.


MANAGEMENT

Mike Grisham - CEO

  • Previously CEO for four venture-backed healthcare/diagnostics companies, raising >$70M in funding with >$300M in returns to investors
  • Former chair of Virginia BIO
  • President of the Virginia Biosciences Health Research Corporation
  • Stanford University, MBA 1977; UC Berkeley, AB 1974

Tony Ward - President, Cell Processing

  • Previously global strategic marketing director of Becton Dickinson’s $325M research cell analysis business
  • Headed commercial operations for eBioscience from start-up through sale to Affymetrix, where he served as SVP/general manager for the business unit
  • Developed and commercialized multiple flow cytometry and assay product technologies
  • Santa Clara University, MBA 1994; California Polytechnic State University, BS Microbiology 1986

Khushroo Gandhi PhD - VP, Product Development & Manufacturing

  • Previously site manager and director of chip process development and manufacturing for Caliper LifeSciences (now a Perkin Elmer company)
  • Was R&D director and principal scientist/materials engineer at Pilkington Barnes-Hind
  • Has scaled-up and transferred into manufacturing multiple microfluidic chip and reagents product lines.
  • USC, PhD Polymer Science & Engineering 1988, MS ChemE 1986; India Institute of Technology, BTech ChemE 1983

Roberto Campos- González PhD - VP, Biology

  • Previously director of antibody product and assay development, and director of molecular assays at Cell Signaling Technology
  • Was director at R&D systems; director of cell signaling research at BD Biosciences
  • University of Ottawa, PhD Biology 1987, MSc Biology 1983; Universidad Autónoma de Guadelajara, BS Biology/Biological Sciences 1977

SCIENTIFIC ADVISORY BOARD

Curt Civin MD - Chairman, SAB

  • University of Maryland School of Medicine – Professor of Pediatrics & Physiology, Director of Center for Stem Cell Biology & Regenerative Medicine, Associate Dean for Research
  • Previously, 30+ years endowed Professor at Johns Hopkins School of Medicine
  • Discovered CD34 stem antigen and Mab, expert in stem cell biology, leukemia, and cellular analysis
  • Amherst College, ScD Hon 2001; Harvard Medical School, MD 1974; Amherst College, BA 1970

Diether Recktenwald PhD

  • BD Fellow Emeritus, former VP Advanced Technology, BD Biosciences
  • Former VP, R&D Amcell Corporation (Miltenyi Biotec affiliate company)
  • Max-Planck-Institut, Dortmund, PhD 1978

James Sturm PhD

  • Director, Princeton Institute for the Science and Technology of Materials, William and Edna Macaleer Professor of Engineering and Applied Science, Professor of Electrical Engineering, Princeton University
  • IEEE Fellow
  • Stanford University, PhD 1985, MSEE 1981; Princeton University, BSE Electrical Engineering (engineering physics) 1979

OTHER ADVISORS

Robert Austin, PhD

  • Princeton University – Professor of Physics; former Director of the Princeton Physical Sciences-Oncology Center
  • Fellow, American Physical Society, and American Association for the Advancement of Science, and American Association of the Arts and Sciences
  • University of Illinois Champaign-Urbana, PhD Physics 1975; Hope College (Holland MI), BA Physics 1968
  • Co-inventor of the DLD technology

Nancy Hardy, MD

  • University of Maryland School of Medicine Marlene & Stewart Greenebaum Comprehensive Cancer Center – Medical Director, Cell Therapy & Graft Engineering; Associate Professor, Medicine; Associate Director, Blood & Marrow Transplantation Program; Medical Director for Cancer Center Quality & Safety
  • Fellow, American College of Physicians
  • Former Chair, NIH Intramural Blood and Marrow Transplant Consortium Relapse Tumor Board
  • Research collaborations within the NCI led to the establishment of CAR-T therapies targeting CD19 and BCMA for B-cell malignancies and multiple myeloma
  • University of Washington, MD 1995; American University, MA International Development 1991; Carroll College (Helena MT), AB 1985

Jason Walsh

  • Previously director of strategic growth for Corning Life Sciences and Corning’s emerging innovations group
  • Was an entrepreneur in residence and engagement manager at McKinsey & Co., Inc., working in the pharmaceutical and medical products and other practice areas
  • Harvard Business School, MBA 1989; St. John’s College (Annapolis MD), BA 1985